{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000283","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.585985+00:00","generated_at":"2026-06-20T18:55:24.228481+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Galecto reports $66M cash as of Dec 31, 2022; updates corporate presentation","bullets":["Cash, cash equivalents, and investments of approx. $66M as of Dec. 31, 2022.","Updated corporate presentation dated Jan. 2023 furnished as an exhibit; no specific details or material changes described.","No financial or operational guidance provided beyond the cash balance update."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000283","json":"https://secwatch.observer/filing/0000950170-23-000283.json","markdown":"https://secwatch.observer/filing/0000950170-23-000283.md","text":"https://secwatch.observer/filing/0000950170-23-000283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017023000283/0000950170-23-000283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017023000283/glto-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:55:24.228481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}